ModalSurv: A Multimodal Deep Survival Framework for Prostate and Bladder Cancer
This work addresses personalized risk stratification for prostate and bladder cancer patients, representing an incremental improvement with domain-specific application.
The paper tackled the problem of predicting time-to-event outcomes in prostate and bladder cancer by developing a multimodal deep survival model, achieving a C-index of 0.818 for prostate cancer and 0.457 for bladder cancer on development sets.
Accurate prediction of time-to-event outcomes is a central challenge in oncology, with significant implications for treatment planning and patient management. In this work, we present ModaliSurv, a multimodal deep survival model utilising DeepHit with a projection layer and inter-modality cross-attention, which integrates heterogeneous patient data, including clinical, MRI, RNA-seq and whole-slide pathology features. The model is designed to capture complementary prognostic signals across modalities and estimate individualised time-to-biochemical recurrence in prostate cancer and time-to-cancer recurrence in bladder cancer. Our approach was evaluated in the context of the CHIMERA Grand Challenge, across two of the three provided tasks. For Task 1 (prostate cancer bio-chemical recurrence prediction), the proposed framework achieved a concordance index (C-index) of 0.843 on 5-folds cross-validation and 0.818 on CHIMERA development set, demonstrating robust discriminatory ability. For Task 3 (bladder cancer recurrence prediction), the model obtained a C-index of 0.662 on 5-folds cross-validation and 0.457 on development set, highlighting its adaptability and potential for clinical translation. These results suggest that leveraging multimodal integration with deep survival learning provides a promising pathway toward personalised risk stratification in prostate and bladder cancer. Beyond the challenge setting, our framework is broadly applicable to survival prediction tasks involving heterogeneous biomedical data.